Why the 'GLP-1 supply' story is undercovered.
The GLP-1 story has been covered, almost entirely, as a demand story. Waitlists. Off-label use. Celebrity before-and-afters. Employer-plan formulary fights. The supply story has its own narrative arc and the trade press has largely missed it. Five points the supply side is actually about, and what each one says about where the obesity-drug category goes from here.
One. The bottleneck is fill-finish, not API. The peptide synthesis capacity for semaglutide and tirzepatide is constrained but expandable; PolyPeptide, Bachem, and Lonza have all been ramping. The harder constraint is aseptic fill-finish, specifically cartridge-and-pen line capacity for the multi-dose injector formats that both Novo Nordisk and Eli Lilly ship in. Building a peptide reactor takes eighteen to twenty-four months. Qualifying a new aseptic fill-finish line takes thirty-six to forty-eight months because the regulatory burden on sterile-injectable manufacturing is much higher than on bulk API. The coverage that frames the supply problem as Novo or Lilly slow to expand the molecule is answering the wrong question; the molecule has not been the binding constraint for at least a year.
Two. Novo's Catalent acquisition is the category's most important 2024 move. In February 2024, Novo Holdings announced an eleven- billion-dollar acquisition of Catalent, with three sterile fill-finish sites (Bloomington, Anagni, Brussels) carved out for transfer to Novo Nordisk. The consumer-press read was generic pharma-M&A. The supply-chain read is that Novo identified the binding constraint, looked at the queue at every contract manufacturer in the world, and decided the only way through was to vertically integrate fill-finish at scale. Lilly's response, the Lilly Medicine Foundry in Indianapolis plus the multi-billion-dollar Concord-North-Carolina and Boone-County-Indiana buildouts, is the same bet on a different timeline. These two companies are now committing more than twenty-five billion dollars combined to sterile- injectable capacity that would not otherwise exist. That is a supply-side answer.
Three. The compounded-GLP-1 market exists because of a regulatory accident, and it is going to end abruptly.503A and 503B compounding pharmacies have, since 2022, been producing compounded semaglutide under the FDA shortage exemption. The result is a parallel market of unknown size (estimates range from hundreds of thousands to low millions of patients) buying a drug that is structurally identical to the branded product from manufacturers who do not pay for clinical trials or carry the same liability profile. The moment the shortage list resolves (and resolution is now a 2025- 2026 question, not a 2027 question, because of the capacity bets in point two), the regulatory exemption ends. The compounded market does not slowly compete away. It vanishes inside a regulatory deadline. Every patient on it transitions back to branded supply or to nothing. Trade-press coverage of compounding has treated it as a structural feature of the obesity- drug market. It is not. It is a transient artifact of a supply gap that is closing.
Four. Manufacturing capacity is going to outpace formulary access. The supply-side projects coming online in 2025 and 2026 are going to bring annual capacity for the category from roughly fifteen million patient-years in 2023 to something in the range of forty to sixty million patient-years by 2027. The bottleneck shifts at that point. It will no longer be can the patient get the drug; it will be will the payer cover the drug. Medicare's 2024 expansion of coverage for cardiovascular indications is the leading edge of this. Commercial-plan carve-outs and prior-auth thresholds are the trailing edge. Whoever is reporting on this category in 2026 will be writing about access-and-affordability stories on a market with ample physical supply, which is the opposite of the 2023-2024 story. The supply chain solves itself before the payment system does.
Five. The next tier of GLP-1s makes the capacity question harder, not easier. Retatrutide, orforglipron, ecnoglutide, the oral formulations, and the non-Novo/non-Lilly entrants (Roche, Pfizer, Amgen, Structure Therapeutics, Viking) are all going to need their own fill-finish capacity, on different formats, on different timelines. The capacity Novo and Lilly are building today is largely format-locked; pen cartridges for current branded products. An oral small-molecule GLP-1 from Lilly or Pfizer does not run on the same line. The category's twenty-fifth- molecule supply chain is going to look almost nothing like the 2024 supply chain, and the planning for it is happening now, mostly at companies who are not in the consumer-press conversation.
The reframe the GLP-1 coverage needs is straightforward. Demand is not the interesting story; demand has been obvious since the SUSTAIN-6 cardiovascular outcomes data in 2016. Demand for semaglutide became inevitable the moment the 2021 STEP trials read out. The interesting story is the supply-side arc, and the interesting story is being driven by ten or fifteen people inside Novo Nordisk, Eli Lilly, Catalent before its acquisition, the FDA's Office of Pharmaceutical Quality, and a handful of contract fill-finish operators. None of them give consumer-press interviews. The trade press that covers them is reading FDA warning letters and capacity announcements, not celebrity Wegovy stories. The first journalist to cover the GLP-1 supply chain as the actual story instead of as the constraint that produces the demand story will be early on a beat that ends up structuring the next decade of the obesity-drug category.
—TJ